California's initiative to produce state-branded, low-cost insulin aimed to disrupt the market and reduce costs for diabetics. However, the project is facing major setbacks, with the timeline for delivery pushed back indefinitely, possibly until 2030. Over 3.5 million Californians rely on insulin, and as of now, contracted manufacturer Civica, Inc. has yet to commence clinical trials or seek FDA approval. The American Diabetes Association has voiced urgent concerns over these delays, emphasizing the critical need for affordable insulin solutions amid rising diabetes cases.
California's ambitious initiative to produce affordable insulin is facing significant delays, putting pressure on millions of diabetics in need of low-cost options.
The American Diabetes Association expressed concern that California's delay in delivering low-cost insulin will see patients waiting until 2030, putting lives at risk.
Collection
[
|
...
]